PureTech Health PLC PureTech Appoints Joseph Bolen as CSO
October 20 2016 - 2:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
20 October 2016
20 October 2016
PureTech Health plc
PureTech Appoints Industry Leader Joseph Bolen as Chief
Scientific Officer
PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a
cross-disciplinary biotech company developing 21(st) century
medicines, today announced the appointment of Joseph Bolen, Ph.D.,
as the Company's Chief Scientific Officer. In this new role, Dr.
Bolen will lead the scientific development and advancement of
PureTech's pipeline and will work closely with the team and
Scientific Advisory Board as the Company identifies and pursues new
modalities to address significant medical needs.
"We are tremendously excited to bring Joe's visionary leadership
and drug development expertise to PureTech," said Daphne Zohar,
Chief Executive Officer of PureTech Health. "Joe is a seasoned
industry expert who brings the ideal balance of rigor and
creativity to the role of CSO, and shares our vision for
identifying and nurturing innovation that can potentially redefine
healthcare."
Joseph Bolen brings to PureTech decades of industry experience
in immunology and oncology, having overseen the discovery and
advancement of more than 30 drugs into clinical development
including Velcade(R), Entyvio(R) and Ninlaro(R). Dr. Bolen most
recently oversaw all aspects of research and development for
Moderna Therapeutics as President and Chief Scientific Officer.
Previously, he was Chief Scientific Officer and Global Head of
Oncology Research at Millennium: The Takeda Oncology Company. Prior
to joining Millennium in 1999, Dr. Bolen held senior R&D
positions at Hoechst Marion Roussel, Schering-Plough (DNAX), and
Bristol-Myers Squibb. He began his career at the NIH, where he
contributed to the discovery of a class of proteins known as
tyrosine kinase oncogenes as key regulators of the immune system.
Dr. Bolen graduated from the University of Nebraska with a B.S.
degree in Microbiology & Chemistry and a Ph.D. in Immunology
and conducted his postdoctoral training in Molecular Virology at
the Kansas State University Cancer Center.
"PureTech Health is one of the most exciting companies in
biotech, advancing truly unique multi-modal solutions to some of
today's most significant healthcare challenges through modulation
of the human nervous and immune adaptive systems," Dr. Bolen said.
"I look forward to working closely with the highly accomplished
PureTech team, the world-class Scientific Advisory Board, and the
vast PureTech network of colleagues across the world who believe
that we are entering into a new era of technology and science
convergence that will profoundly impact our understanding of
disease and fundamentally change the practice of medicine. Our
mission at PureTech Health is to collaborate broadly with
biomedical science and technology leaders in order to generate the
most exciting ideas and then to transform these concepts into
breakthrough medicines."
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary biotech company creating 21(st) century
medicines that modulate the adaptive human systems. Our therapies
target the immune, nervous, and gastro-intestinal systems by
addressing the underlying pathophysiology of disease across
multiple dimensions rather than through a single receptor or
pathway. We are advancing more than 20 clinical studies across our
pipeline, with five human proof-of-concept studies and multiple
pivotal or registration studies expected to read out in the next
two years. PureTech Health's pipeline is sourced and filtered by
the world's leading scientific experts, who along with PureTech's
leading team and board analyse more than 650 scientific discoveries
per year to identify the most promising opportunities for patients.
This process places the PureTech Health on the cutting edge of
ground-breaking science and technological innovation and leads the
Company between and beyond existing disciplines. For more
information, visit www.puretechhealth.com or connect with us on
Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward- looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the company's regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Listing Rules and the
Disclosure and Transparency Rules, neither the company nor any
other party intends to update or revise these forward- looking
statements, whether as a result of new information, future events
or otherwise.
# # #
For further information, please contact:
PureTech +1 617 651 3156
Allison Mead, Director, Communications
and Investor Relations
FTI Consulting (Communications +44 (0) 20 3727
adviser to PureTech) 1000
Ben Atwell
Matthew Cole
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADBBDGXUBBGLC
(END) Dow Jones Newswires
October 20, 2016 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2023 to Apr 2024